Outcomes of hospitalised immunocompromised patients, compared with immunocompetent patients.

Odds ratios (ORs) from multivariable logistic regression and 95% confidence intervals (CIs) for outcomes of death, critical care admission, noninvasive and invasive ventilation, adjusted for age, sex, ethnicity, socioeconomic deprivation, chronic cardiac, pulmonary and renal disease, and vaccination status.</p

Flow diagram of patients in the study.

The total number of participants entered into the ISARIC CCP-UK database, reasons for exclusion, and numbers of patients in each category of immunocompromise are shown. CCP-UK, Clinical Characterisation Protocol in the United Kingdom; COVID-19, Coronavirus Disease 2019; ISARIC, International Severe Acute Respiratory and emerging Infection Consortium.</p

Outcomes by reason for immunocompromise.

Data are numbers of patients (%).</p

STROBE Checklist.

(DOCX)</p

Outcomes by reason for immunocompromise.

(DOCX)</p

Outcomes of hospitalised immunocompromised patients, compared with immunocompetent patients over the first 4 pandemic waves in the UK.

Odds ratios (ORs) from multivariable logistic regression and 95% confidence intervals (CIs) for outcomes of death, broken down by pandemic wave, adjusted for age, sex, ethnicity, socioeconomic deprivation, comorbidity count (not including the immunocompromising condition), and vaccination status. Wave 1 was 17 January to 31 August 2020; wave 2 was 1 September 2020 to 31 March 2021; wave 3 was 1 April 2021 to 12 December 2021; and wave 4 was 13 December 2021 to 28 February 2022.</p

Number of admissions of immunocompetent and immunocompromised patients over time.

(DOCX)</p

Comorbidities in immunocompetent versus immunocompromised patients stratified by pandemic wave.

(DOCX)</p

Number (%) of patients receiving steroids and tocilizumab by immune status and pandemic wave.

(DOCX)</p

Sensitivity analysis for the primary and secondary outcomes using imputation of missing data.

(DOCX)</p